{
  "PAAD": {
    "cancer_name": "Pancreatic Adenocarcinoma",
    "other_codes_used_for_data_gathering": {
      "NCIt": "C8294",
      "UMLS": "C0281361"
    },
    "associated_genes": [
      {
        "gene_symbol": "KRAS",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID:33303929|PMID:31860935|cBioPortal",
          "mutations": [
            "Missense (G12D, G12V, G12R, G12C, G13D)",
            "Deletion",
            "Insertion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: Missense mutations in KRAS are associated with PAAD and used for diagnosis.",
          "therapeutic_relevance": "clinical trials such as NCT07020221 are actively testing inhibitors of the actionable missense mutation KRAS G12D which is frequent in PAAD. KRAS G12C inhibitors are being explored in clinical trials."
        }
      },
      {
        "gene_symbol": "TP53",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID:33303929|PMID:31860935|cBioPortal",
          "mutations": [
            "Missense",
            "Truncating",
            "Deletion",
            "Splice site"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: Mutations in TP53 are associated with PAAD and can be used for diagnosis and prognosis.",
          "therapeutic_relevance": "TP53 mutations can affect response to chemotherapy and radiation therapy."
        }
      },
      {
        "gene_symbol": "CDKN2A",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID:33303929|PMID:31860935|cBioPortal",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense",
            "Splice site"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: Loss of CDKN2A expression or mutations are associated with PAAD.",
          "therapeutic_relevance": "CDKN2A loss may predict sensitivity to certain therapies."
        }
      },
      {
        "gene_symbol": "SMAD4",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID:33303929|PMID:31860935|cBioPortal",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: SMAD4 loss is associated with PAAD and can be used for diagnosis and prognosis.",
          "therapeutic_relevance": "SMAD4 loss may predict resistance to certain therapies."
        }
      },
      {
        "gene_symbol": "ARID1A",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID:22820354|cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ARID1A mutations are associated with PAAD.",
          "therapeutic_relevance": "ARID1A mutations may predict sensitivity to certain therapies."
        }
      },
      {
        "gene_symbol": "ATM",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID:25355527|ClinVar",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: ATM mutations are associated with PAAD.",
          "therapeutic_relevance": "ATM mutations may predict sensitivity to PARP inhibitors."
        }
      },
      {
        "gene_symbol": "BRCA1",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID:28725275|ClinVar",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion",
            "Splice site"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: BRCA1 mutations are associated with PAAD.",
          "therapeutic_relevance": "BRCA1 mutations predict sensitivity to platinum-based chemotherapy and PARP inhibitors."
        }
      },
      {
        "gene_symbol": "BRCA2",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID:28725275|ClinVar",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion",
            "Splice site"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: BRCA2 mutations are associated with PAAD.",
          "therapeutic_relevance": "BRCA2 mutations predict sensitivity to platinum-based chemotherapy and PARP inhibitors."
        }
      },
      {
        "gene_symbol": "PALB2",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID:20628693|ClinVar",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion",
            "Splice site"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: PALB2 mutations are associated with PAAD.",
          "therapeutic_relevance": "PALB2 mutations may predict sensitivity to platinum-based chemotherapy and PARP inhibitors."
        }
      },
      {
        "gene_symbol": "STK11",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID:12629560|cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: STK11 mutations are associated with PAAD.",
          "therapeutic_relevance": "STK11 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "CDKN2B",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "cBioPortal",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: CDKN2B deletions are associated with PAAD.",
          "therapeutic_relevance": "CDKN2B loss may predict sensitivity to certain therapies."
        }
      },
      {
        "gene_symbol": "GNAS",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID:24390349|cBioPortal",
          "mutations": [
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: GNAS mutations are associated with PAAD.",
          "therapeutic_relevance": "GNAS mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "KMT2C",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: KMT2C mutations are associated with PAAD.",
          "therapeutic_relevance": "KMT2C mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "RNF43",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: RNF43 mutations are associated with PAAD.",
          "therapeutic_relevance": "RNF43 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "ROBO2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID:24859626",
          "mutations": [
            "Deletion",
            "Truncating"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ROBO2 mutations are associated with PAAD.",
          "therapeutic_relevance": "ROBO2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "CTNNA1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID:24859626",
          "mutations": [
            "Deletion",
            "Truncating"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: CTNNA1 mutations are associated with PAAD.",
          "therapeutic_relevance": "CTNNA1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "APC",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: APC mutations are associated with PAAD.",
          "therapeutic_relevance": "APC mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "ERBB4",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ERBB4 mutations are associated with PAAD.",
          "therapeutic_relevance": "ERBB4 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "MAP2K4",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: MAP2K4 mutations are associated with PAAD.",
          "therapeutic_relevance": "MAP2K4 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "MUC16",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: MUC16 mutations are associated with PAAD.",
          "therapeutic_relevance": "MUC16 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "PIK3CA",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Missense",
            "Amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: PIK3CA mutations are associated with PAAD.",
          "therapeutic_relevance": "PIK3CA mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "TGFBR2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: TGFBR2 mutations are associated with PAAD.",
          "therapeutic_relevance": "TGFBR2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "ARID2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ARID2 mutations are associated with PAAD.",
          "therapeutic_relevance": "ARID2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "FBXW7",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: FBXW7 mutations are associated with PAAD.",
          "therapeutic_relevance": "FBXW7 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "GNAS",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: GNAS mutations are associated with PAAD.",
          "therapeutic_relevance": "GNAS mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "KMT2D",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: KMT2D mutations are associated with PAAD.",
          "therapeutic_relevance": "KMT2D mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "NOTCH1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: NOTCH1 mutations are associated with PAAD.",
          "therapeutic_relevance": "NOTCH1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "PREX2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: PREX2 mutations are associated with PAAD.",
          "therapeutic_relevance": "PREX2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "RREB1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: RREB1 mutations are associated with PAAD.",
          "therapeutic_relevance": "RREB1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "SF3B1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: SF3B1 mutations are associated with PAAD.",
          "therapeutic_relevance": "SF3B1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "SMARCA4",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense",
            "Deletion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: SMARCA4 mutations are associated with PAAD.",
          "therapeutic_relevance": "SMARCA4 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "SPOP",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: SPOP mutations are associated with PAAD.",
          "therapeutic_relevance": "SPOP mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "ZFHX3",
        "gene_info": {
          "association_strength": "weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ZFHX3 mutations are associated with PAAD.",
          "therapeutic_relevance": "ZFHX3 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "EPCAM",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID:21147647",
          "mutations": [
            "Deletion"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: EPCAM deletions are associated with PAAD.",
          "therapeutic_relevance": "EPCAM deletions may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "MLH1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID:21147647",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: MLH1 mutations are associated with PAAD.",
          "therapeutic_relevance": "MLH1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "MSH2",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID:21147647",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: MSH2 mutations are associated with PAAD.",
          "therapeutic_relevance": "MSH2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "MSH6",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID:21147647",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: MSH6 mutations are associated with PAAD.",
          "therapeutic_relevance": "MSH6 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "PMS2",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID:21147647",
          "mutations": [
            "Deletion",
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "diagnostic: PMS2 mutations are associated with PAAD.",
          "therapeutic_relevance": "PMS2 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "LATS1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: LATS1 mutations are associated with PAAD.",
          "therapeutic_relevance": "LATS1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "NF1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: NF1 mutations are associated with PAAD.",
          "therapeutic_relevance": "NF1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "PPP6C",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: PPP6C mutations are associated with PAAD.",
          "therapeutic_relevance": "PPP6C mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "RASA1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "cBioPortal",
          "mutations": [
            "Truncating",
            "Missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: RASA1 mutations are associated with PAAD.",
          "therapeutic_relevance": "RASA1 mutations may affect response to certain therapies."
        }
      },
      {
        "gene_symbol": "ROS1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "cBioPortal",
          "mutations": [
            "Fusion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "diagnostic: ROS1 fusions are associated with PAAD.",
          "therapeutic_relevance": "ROS1 fusions may predict sensitivity to targeted therapies."
        }
      }
    ],
    "molecular_subtypes": [
      "Squamous",
      "Pancreatic Progenitor",
      "Immunogenic",
      "Aberrantly Differentiated Endocrine Exocrine (ADEX)",
      "Basal-like",
      "Classical",
      "Exocrine-like"
    ],
    "associated_pathways": {
      "ar_signaling": "no",
      "ar_and_steroid_synthesis_enzymes": "no",
      "steroid_inactivating_genes": "no",
      "down_regulated_by_androgen": "no",
      "rtk_ras_pi3k_akt_signaling": "yes",
      "rb_pathway": "yes",
      "cell_cycle_pathway": "yes",
      "hippo_pathway": "yes",
      "myc_pathway": "yes",
      "notch_pathway": "yes",
      "nrf2_pathway": "no",
      "pi3k_pathway": "yes",
      "rtk_ras_pathway": "yes",
      "tp53_pathway": "yes",
      "wnt_pathway": "yes",
      "cell_cycle_control": "yes",
      "p53_signaling": "yes",
      "notch_signaling": "yes",
      "dna_damage_response": "yes",
      "other_growth_proliferation_signaling": "yes",
      "survival_cell_death_regulation_signaling": "yes",
      "telomere_maintenance": "no",
      "rtk_signaling_family": "yes",
      "pi3k_akt_mtor_signaling": "yes",
      "ras_raf_mek_erk_jnk_signaling": "yes",
      "angiogenesis": "yes",
      "folate_transport": "no",
      "invasion_and_metastasis": "yes",
      "tgf_\u03b2_pathway": "yes",
      "oncogenes_associated_with_epithelial_ovarian_cancer": "no",
      "regulation_of_ribosomal_protein_synthesis_and_cell_growth": "yes"
    }
  },
  "BRCA": {
    "cancer_name": "Invasive Breast Carcinoma",
    "other_codes_used_for_data_gathering": {
      "NCIt": "C9245",
      "UMLS": "C0853879"
    },
    "associated_genes": [
      {
        "gene_symbol": "TP53",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID: 22820485|PMID: 29249953|cBioPortal",
          "mutations": [
            "missense",
            "truncating",
            "deletion",
            "splice site",
            "copy number alteration"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "TP53 mutations are frequently detected in invasive breast carcinoma and can be used for molecular subtyping and risk stratification.",
          "therapeutic_relevance": "TP53 status can influence response to chemotherapy and targeted therapies; clinical trials are exploring TP53-directed therapies."
        }
      },
      {
        "gene_symbol": "PIK3CA",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID: 15322331|PMID: 28728864|cBioPortal",
          "mutations": [
            "missense (hotspot mutations such as H1047R, E545K)",
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "PIK3CA mutations are common in hormone receptor-positive breast cancer and can be used for molecular subtyping.",
          "therapeutic_relevance": "PIK3CA mutations predict response to PI3K inhibitors such as alpelisib."
        }
      },
      {
        "gene_symbol": "ERBB2",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID: 11000137|PMID: 21471963|cBioPortal",
          "mutations": [
            "amplification",
            "overexpression",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "ERBB2 (HER2) amplification/overexpression is a key diagnostic marker for HER2-positive breast cancer.",
          "therapeutic_relevance": "ERBB2 amplification/overexpression predicts response to HER2-targeted therapies such as trastuzumab and pertuzumab."
        }
      },
      {
        "gene_symbol": "BRCA1",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID: 8162342|GeneReviews",
          "mutations": [
            "truncating",
            "splice site",
            "deletion",
            "duplication",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "BRCA1 mutations increase risk of invasive breast carcinoma and can be used for risk assessment and genetic counseling.",
          "therapeutic_relevance": "BRCA1 mutations predict response to PARP inhibitors and platinum-based chemotherapy."
        }
      },
      {
        "gene_symbol": "BRCA2",
        "gene_info": {
          "association_strength": "very strong",
          "reference": "PMID: 8162343|GeneReviews",
          "mutations": [
            "truncating",
            "splice site",
            "deletion",
            "duplication",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "BRCA2 mutations increase risk of invasive breast carcinoma and can be used for risk assessment and genetic counseling.",
          "therapeutic_relevance": "BRCA2 mutations predict response to PARP inhibitors and platinum-based chemotherapy."
        }
      },
      {
        "gene_symbol": "PTEN",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID: 11929873|cBioPortal",
          "mutations": [
            "truncating",
            "deletion",
            "missense",
            "promoter methylation"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "PTEN loss can be used for molecular subtyping.",
          "therapeutic_relevance": "PTEN loss may predict resistance to some targeted therapies."
        }
      },
      {
        "gene_symbol": "CDKN2A",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID: 8637969|cBioPortal",
          "mutations": [
            "deletion",
            "truncating",
            "missense",
            "promoter methylation"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "CDKN2A inactivation can be used for molecular subtyping.",
          "therapeutic_relevance": "CDKN2A loss may predict response to CDK4/6 inhibitors."
        }
      },
      {
        "gene_symbol": "MAP3K1",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "MAP3K1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "MAP3K1 mutations may influence response to MAPK pathway inhibitors."
        }
      },
      {
        "gene_symbol": "GATA3",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 18703723|cBioPortal",
          "mutations": [
            "missense",
            "truncating"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "GATA3 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "GATA3 mutations may influence response to hormone therapies."
        }
      },
      {
        "gene_symbol": "AKT1",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 17921472|cBioPortal",
          "mutations": [
            "missense (hotspot mutations such as E17K)"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "AKT1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "AKT1 mutations may predict response to AKT inhibitors."
        }
      },
      {
        "gene_symbol": "RB1",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 20147994|cBioPortal",
          "mutations": [
            "truncating",
            "deletion",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "RB1 loss can be used for molecular subtyping.",
          "therapeutic_relevance": "RB1 loss may influence response to CDK4/6 inhibitors."
        }
      },
      {
        "gene_symbol": "CDH1",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 9349768|GeneReviews",
          "mutations": [
            "truncating",
            "missense",
            "deletion"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "CDH1 mutations increase risk of lobular breast carcinoma.",
          "therapeutic_relevance": "No specific therapeutic implications known."
        }
      },
      {
        "gene_symbol": "NF1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "NF1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "NF1 mutations may influence response to MEK inhibitors."
        }
      },
      {
        "gene_symbol": "ATM",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "ATM mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "ATM mutations may predict response to PARP inhibitors."
        }
      },
      {
        "gene_symbol": "CHEK2",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 12629595|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "CHEK2 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "CHEK2 mutations may predict response to DNA damaging agents."
        }
      },
      {
        "gene_symbol": "PALB2",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID: 20056882|GeneReviews",
          "mutations": [
            "truncating",
            "missense",
            "deletion"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "PALB2 mutations increase risk of invasive breast carcinoma and can be used for risk assessment and genetic counseling.",
          "therapeutic_relevance": "PALB2 mutations predict response to PARP inhibitors and platinum-based chemotherapy."
        }
      },
      {
        "gene_symbol": "RAD51C",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 20164728|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "RAD51C mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "RAD51C mutations may predict response to PARP inhibitors."
        }
      },
      {
        "gene_symbol": "RAD51D",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 20164728|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "RAD51D mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "RAD51D mutations may predict response to PARP inhibitors."
        }
      },
      {
        "gene_symbol": "BARD1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "BARD1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "BARD1 mutations may predict response to PARP inhibitors."
        }
      },
      {
        "gene_symbol": "MLH1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 8525213|cBioPortal",
          "mutations": [
            "truncating",
            "missense",
            "promoter methylation"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "MLH1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "MLH1 mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "MSH2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 8525213|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "MSH2 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "MSH2 mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "MSH6",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 8525213|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "MSH6 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "MSH6 mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "PMS2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 8525213|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "germline/somatic",
          "diagnostic_implication": "PMS2 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "PMS2 mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "POLE",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 23222526|cBioPortal",
          "mutations": [
            "missense (proofreading domain)"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "POLE mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "POLE mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "POLD1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 23222526|cBioPortal",
          "mutations": [
            "missense (proofreading domain)"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "POLD1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "POLD1 mutations may predict response to immunotherapy."
        }
      },
      {
        "gene_symbol": "FGFR1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "FGFR1 amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "FGFR1 amplification may predict response to FGFR inhibitors."
        }
      },
      {
        "gene_symbol": "FGFR2",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "FGFR2 amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "FGFR2 amplification may predict response to FGFR inhibitors."
        }
      },
      {
        "gene_symbol": "FGFR3",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "FGFR3 amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "FGFR3 amplification may predict response to FGFR inhibitors."
        }
      },
      {
        "gene_symbol": "CCND1",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "CCND1 amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "CCND1 amplification may predict response to CDK4/6 inhibitors."
        }
      },
      {
        "gene_symbol": "MYC",
        "gene_info": {
          "association_strength": "moderate",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "amplification"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "MYC amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "MYC amplification may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "ESR1",
        "gene_info": {
          "association_strength": "strong",
          "reference": "PMID: 24336242|cBioPortal",
          "mutations": [
            "missense (ligand-binding domain)"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "ESR1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "ESR1 mutations may predict resistance to endocrine therapies."
        }
      },
      {
        "gene_symbol": "ARID1A",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "ARID1A mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "ARID1A mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "TBX3",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 15345648|cBioPortal",
          "mutations": [
            "amplification",
            "overexpression"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "TBX3 amplification can be used for molecular subtyping.",
          "therapeutic_relevance": "TBX3 amplification may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "FOXA1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "FOXA1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "FOXA1 mutations may influence response to hormone therapies."
        }
      },
      {
        "gene_symbol": "KMT2C",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "KMT2C mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "KMT2C mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "KMT2D",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "KMT2D mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "KMT2D mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "SF3B1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "SF3B1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "SF3B1 mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "CBFB",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "fusion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "CBFB fusions can be used for molecular subtyping.",
          "therapeutic_relevance": "CBFB fusions may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "RUNX1",
        "gene_info": {
          "association_strength": "very weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "fusion"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "RUNX1 fusions can be used for molecular subtyping.",
          "therapeutic_relevance": "RUNX1 fusions may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "MAP2K4",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "MAP2K4 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "MAP2K4 mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "FBXW7",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "FBXW7 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "FBXW7 mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "PPP2R1A",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "PPP2R1A mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "PPP2R1A mutations may influence response to targeted therapies."
        }
      },
      {
        "gene_symbol": "PIK3R1",
        "gene_info": {
          "association_strength": "weak",
          "reference": "PMID: 21464826|cBioPortal",
          "mutations": [
            "truncating",
            "missense"
          ],
          "mutation_origin": "somatic",
          "diagnostic_implication": "PIK3R1 mutations can be used for molecular subtyping.",
          "therapeutic_relevance": "PIK3R1 mutations may influence response to targeted therapies."
        }
      }
    ],
    "molecular_subtypes": [
      "Luminal A",
      "Luminal B",
      "HER2-enriched",
      "Basal-like",
      "Claudin-low",
      "Triple-negative"
    ],
    "associated_pathways": {
      "ar_signaling": "no",
      "ar_and_steroid_synthesis_enzymes": "no",
      "steroid_inactivating_genes": "no",
      "down_regulated_by_androgen": "no",
      "rtk_ras_pi3k_akt_signaling": "yes",
      "rb_pathway": "yes",
      "cell_cycle_pathway": "yes",
      "hippo_pathway": "no",
      "myc_pathway": "yes",
      "notch_pathway": "no",
      "nrf2_pathway": "no",
      "pi3k_pathway": "yes",
      "rtk_ras_pathway": "yes",
      "tp53_pathway": "yes",
      "wnt_pathway": "no",
      "cell_cycle_control": "yes",
      "p53_signaling": "yes",
      "notch_signaling": "no",
      "dna_damage_response": "yes",
      "other_growth_proliferation_signaling": "yes",
      "survival_cell_death_regulation_signaling": "yes",
      "telomere_maintenance": "no",
      "rtk_signaling_family": "yes",
      "pi3k_akt_mtor_signaling": "yes",
      "ras_raf_mek_erk_jnk_signaling": "yes",
      "angiogenesis": "no",
      "folate_transport": "no",
      "invasion_and_metastasis": "no",
      "tgf_\u03b2_pathway": "no",
      "oncogenes_associated_with_epithelial_ovarian_cancer": "no",
      "regulation_of_ribosomal_protein_synthesis_and_cell_growth": "yes"
    }
  }
}